05 June 2026
05 June 2026
In this episode, two oncology analysts share their insights from the ASCO show floor, while talking through the readouts that excited them most.
The Regeneron-partnered biotech is currently progressing its lead asset, zolucatetide, in desmoid tumours.
According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai-3 model.
Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss.
The FDA's decision follows data from a Phase Ib study on salanersen.
If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
